Summary
Oncolytic virus that selectively targets and eradicates tumor cells and immune checkpoint blockade that unleashes host anti-tumor immune responses show synergistic effects against cancer. This combination holds great promise for future treatment of a broad range of cancers in patients.
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Author Manuscript Published OnlineFirst on September 16, 2015; DOI: 10.1158/1078-0432. CCR-15-1769 In this issue of Clinical Cancer Research, Rojas and colleagues report that combining an oncolytic virus and the immune checkpoint blockade inhibitor anti-CTLA-4 resulted in significantly better anti-tumor responses than either modality alone in two different mouse tumor models (1) . These two therapies work in different ways. The oncolytic virus is tumor-selective due to specific deletion of genes that are crucial for replication of the virus in normal cells but dispensable in cancer cells (2) .
The immune checkpoint inhibitor, an antibody against cytotoxic T-lymphocyteassociated antigen 4 (CTLA-4), was the first drug of this kind approved by the FDA for treatment of cancer patients. CTLA-4 is exclusively expressed on T cells and regulates the amplitude of early T cell activation (3) . In this study, the authors revealed that administration of oncolytic virus and anti-CTLA-4 antibody resulted in activation of both innate and adaptive immune responses against the tumor and blocked immunosuppressive mechanisms within the tumor microenvironment.
The ability of viruses to lyse cancer cells has been well recognized.
Genetically modified oncolytic viruses such as herpes, vaccinia and reovirus have demonstrated encouraging results against cancers in both mouse models and human trials (2) . Administration of talimogene laherparepvec (T-VEC) in human melanoma trials in particular has demonstrated encouraging responses at both the injected and distant tumor sites, including visceral lesions. T-VEC is a genetically modified herpes type 1 oncolytic virus that contains an insertion of the granulocyte-macrophage colony-stimulating factor (GM-CSF) gene that promotes local antigen presentation and systemic antitumor immunity (4). A similar approach using the vaccinia virus, JX-594, containing GM-CSF and deletion of the thymidine kinase gene has also generated therapeutic responses in patients with advanced hepatocellular carcinoma and these responses were also observed at distant untreated tumor sites (5). In the clinic, the combination of Ipilimumab (monoclonal antibody to CTLA-4) and T-VEC is currently being tested in a phase III trial to treat advanced melanoma patients. The preliminary data are promising, demonstrating a significant synergistic effect (11) . A further trial involving the checkpoint blocking antibody anti-PD-1 with oncolytic virus is planned for the treatment of melanoma patients (11) . Whether this combined therapy leads to better control of distal tumor metastases remains to be seen.
In summary, the combination of oncolytic virus and anti-CTLA-4 therapy appears to hold great promise for controlling cancer progression in patients and also opens up new options for combining oncolytic virus with other immunomodulatory therapies.
Additional approaches that amplify and prolong antitumor immune responses such the agonist antibody anti-CD137 has been shown to effectively combine with oncolytic virus to significantly reduce tumor growth and metastases in mouse models (12) 
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